Containing Pandemic Influenza with Antiviral Agents

American Journal of Epidemiology

Volumn 159, Issue 7, 2004, Pages 623-633

  Longini Jr , Ira M ^a   Halloran, M Elizabeth ^a   Nizam, Azhar ^a   Yang, Yang ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

Antiviral agents; Bioterrorism; Computer simulation; Disease outbreaks; Influenza; Influenza A virus; Influenza vaccine; Monte Carlo method

Indexed keywords

ANTIVIRUS AGENT;

BIOLOGICAL WEAPON; DISEASE CONTROL; DRUG PRESCRIBING; INFLUENZA; VIRAL DISEASE;

ADULT; ARTICLE; BIOLOGICAL WARFARE; CHILD; EPIDEMIC; HUMAN; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A; MORTALITY; SIMULATION; UNITED STATES;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; BIOTERRORISM; CHILD, PRESCHOOL; COMPUTER SIMULATION; DISEASE OUTBREAKS; HUMANS; INFANT; INFANT, NEWBORN; INFLUENZA VACCINES; INFLUENZA, HUMAN; MIDDLE AGED; MODELS, THEORETICAL; STOCHASTIC PROCESSES; UNITED STATES;

NORTH AMERICA; UNITED STATES;

EID: 1642462098     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/aje/kwh092     Document Type: Article

References (43)

1. Thompson WW, Shay DK, Weintraub W, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003;289:179-86.
2. Kilbourne ED. The influenza viruses and influenza. New York, NY: Academic Press, 1975.
3. Hayden FG. Perspectives on antiviral use during pandemic influenza. Philos Trans R Soc Lond B Biol Sci 2001;356:1877-84.
4. Laver G, Garman E. The origin and control of pandemic influenza. Science 2001;293:1776-7.
5. Webby RJ, Webster RG. Are we ready for pandemic influenza? Science 2003;302:1519-22.
6. NIAID biodefense research agenda for category B and C priority pathogens. Bethesda, MD: National Institute of Allergy and Infectious Diseases, 2003. (NIH publication no. 03-5315) (http://www.niaid.nih.gov/biodefense/research/categorybandc.pdf).
7. Madjid M, Lillibridge S, Mirhaji P, et al. Influenza as a bioweapon. J R Soc Med 2003;96:345-6.
8. Hayden FG, Aoki FY. Amantadine, rimantadine, and related agents, antiviral agents. In: Yu V, Meigan T, Barriere S, eds. Antimicrobial therapy and vaccines. Baltimore, MD: Williams and Wilkins, 1999:1344-65.
9. Hayden FG, Gubareva LV, Monto AS, et al. Inhaled zanamivir for the prevention of influenza in families. N Engl J Med 2000;343:1282-9.
10. Monto AS, Robinson DP, Herlocher ML, et al. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. JAMA 1999;282:31-5.
11. Welliver R, Monto AS, Carewicz O, et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA 2001;285:748-54.
12. Halloran ME, Longini IM, Struchiner CJ. Design and interpretation of vaccine field studies. Epidemiol Rev 1999;21:73-88.
13. Galbraith AW, Oxford JS, Schild GC, et al. Study of 1-adamantanamine hydrochloride used prophylactically during the Hong Kong influenza epidemic in the family environment. Bull World Health Organ 1969;41:667-82.
14. Yang Y, Longini IM. New methods for the estimation of influenza antiviral agent efficacy. Presented at the Joint Statistical Meetings, San Francisco, California, August 3-7, 2003.
15. Monto AS, Gunn RA, Bandyk MG, et al. Prevention of Russian influenza by amantadine. JAMA 1979;241:1003-7.
16. Belshe RB, Mendelman PM, Treanor J, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med 1998;338:1405-12.
17. Belshe RB, Gruber WC, Mendelman PM, et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr 2000;136:168-75.
18. Longini IM, Halloran ME, Nizam A, et al. Estimation of the efficacy of live, attenuated influenza vaccine from a two-year, multi-center vaccine trial: implications for influenza epidemic control. Vaccine 2000;18:1902-9.
19. Halloran ME, Longini IM, Cowart DM, et al. Community trials of vaccination and the epidemic prevention potential. Vaccine 2002;20:3254-62.
20. Elveback LR, Fox JP, Ackerman E, et al. An influenza simulation model for immunization studies. Am J Epidemiol 1976;103:152-65.
21. Halloran ME, Longini IM, Nizam A, et al. Containing bioterrorist smallpox. Science 2002;128:1428-32.
22. Census 2000. Washington, DC: US Census Bureau, 2001. (http://www.census.gov/). (Posted July 25, 2001).
23. Jordan WS. Mechanisms of spread of Asian influenza. Am Rev Respir Dis 1961;83:29-35.
24. Longini IM, Ackerman E, Elveback LR. An optimization model for influenza A epidemics. Math Biosci 1978;38:141-57.
25. 0 in models for infectious diseases in heterogeneous populations. Math Biol 1990;28:365-82.
26. Hill AN, Longini IM. The critical vaccination fraction for heterogeneous epidemic models. Math Biosci 2002;181:85-106.
27. Pandemic influenza. Atlanta, GA: National Vaccine Program Office, Centers for Disease Control and Prevention, 2002. (http://www.hhs.gov/nvpo/pandemics/). (Last reviewed March 20, 2002).
28. Update: severe acute respiratory syndrome-United States, 2003. MMWR Morb Mortal Wkly Rep 2003;52:332, 334-6.
29. Donnelly CA, Ghani AC, Leung GM, et al. Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong. Lancet 2003;361:1761-6.
30. Fox JP, Elveback LR. Herd immunity-changing concepts. In: Viral immunology and immunopathology. Philadelphia, PA: WB Saunders, 1975:273-90.
31. Monto AS, Koopman JS, Longini IM. The Tecumseh study of illness. XII. Influenza infection and disease, 1976-1981. Am J Epidemiol 1985;121:811-22.
32. Glezen P, Couch RB. Interpandemic influenza in the Houston area, 1974-76. N Engl J Med 1978;298:587-92.
33. Longini IM. The generalized discrete-time epidemic model with immunity: a synthesis. Math Biosci 1986;82:19-41.
34. Rvachev LA, Longini IM. A mathematical model for the global spread of influenza. Math Biosci 1985;75:3-22.
35. Stilianakis NI, Perelson AS, Hayden FG. Emergence of drug resistance during an influenza epidemic: insights from a mathematical model. J Infect Dis 1998;177:863-73.
36. Ferguson NM, Mallett S, Jackson H, et al. A population-dynamic model for evaluating the potential spread of drug-resistant influenza virus infections during community-based use of antivirals. J Antimicrob Chemother 2003;51:977-90.
37. Glezen P, Couch RB. Influenza viruses. In: Evans AS, ed. Virus infections in humans-epidemiology and control. 3rd ed. New York, NY: Plenum, 1989:419-49.
38. Longini IM Jr, Fine PE, Thacker SB. Predicting the global spread of new infectious agents. Am J Epidemiol 1986;123:383-91.
39. Meltzer MI, Cox NJ, Fukuda K. The economic impact of pandemic influenza in the United States: priorities for intervention. Emerg Infect Dis 1999;5:659-71.
40. Longini IM, Koopman JS, Haber M, et al. Statistical inference for infectious diseases: risk-specific household and community transmission parameters. Am J Epidemiol 1988;128:845-59.
41. Addy CL, Longini IM, Haber MS. A generalized stochastic model for the analysis of infectious disease final size data. Biometrics 1991;47:961-74.
42. Seaholm SK, Ackerman E, Wu SC. Latin hypercube sampling and the sensitivity analysis of a Monte Carlo epidemic model. Int J Biomed Comput 1988;23:97-112.
43. 0 and secure vaccination coverage. J R Stat Soc (B) 2001;63:705-15.